TY  - JOUR
A1  - Verboket, René
A1  - Söhling, Nicolas
A1  - Heilani, Myriam Widad
A1  - Fremdling, Charlotte
A1  - Schaible, Alexander
A1  - Schröder, Katrin
A1  - Brune, Jan C.
A1  - Marzi, Ingo
A1  - Henrich, Dirk
T1  - The induced membrane technique - the filling matters: evaluation of different forms of membrane filling with and without bone marrow mononuclear cells (BMC) in large femoral bone defects in rats
T2  - Biomedicines
N2  - The Masquelet technique is used to treat large bone defects; it is a two-stage procedure based on an induced membrane. To improve the induced membrane process, demineralized bone matrix in granular (GDBM) and fibrous form (f-DBM) was tested with and without bone marrow mononuclear cells (BMC) as filling of the membrane against the gold standard filling with syngeneic cancellous bone (SCB). A total of 65 male Sprague–Dawley rats obtained a 5 mm femoral defect. These defects were treated with the induced membrane technique and filled with SCB, GDBM, or f-DBM, with or without BMC. After a healing period of eight weeks, the femurs were harvested and submitted for histological, radiological, and biomechanical analyses. The fracture load in the defect zone was lower compared to SCB in all groups. However, histological analysis showed comparable new bone formation, bone mineral density, and cartilage proportions and vascularization. The results suggest that f-DBM in combination with BMC and the induced membrane technique cannot reproduce the very good results of this material in large, non-membrane coated bone defects, nevertheless it supports the maturation of new bone tissue locally. It can be concluded that BMC should be applied in lower doses and inflammatory cells should be removed from the cell preparation before implantation.
KW  - critical size defect
KW  - tissue engineering
KW  - BMNC
KW  - Masquelet technique
KW  - bone regeneration
Y1  - 2022
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/69280
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-692805
SN  - 2227-9059
N1  - This research was in part funded by the German Institute for Cell and Tissue Replacement (DIZG, gemeinnützige GmbH), 12555 Berlin, Germany.
VL  - 10
IS  - 3, art. 642
SP  - 1
EP  - 17
PB  - MDPI
CY  - Basel
ER  -